When a pharmacy removes all its CBD dietary supplements from its shelves overnight, it highlights how pharmacy trends are not just about installing a robot or redesigning a website. Since May 15, 2026, the sale of food products containing cannabidiol has been banned in France, including in pharmacies and parapharmacies. This regulatory break reshapes the wellness offering and forces teams to react quickly.
Ban on CBD food products: what changes concretely in pharmacies
The measure affects a segment that had taken a significant place on the shelves: gummies, functional infusions, cannabidiol-based supplements. Overnight, these references become unsellable. Pharmacies that do not immediately adapt their assortment expose themselves to increased inspections and legal risks.
On the ground, the most common response is to refocus the wellness offering on phytotherapy and micronutrition. Valerian, passionflower, and magnesium bisglycinate take the place left vacant by CBD. For the teams, this means retraining counter advice and updating product sheets on online sales platforms.
A detailed follow-up of these regulatory developments and their practical consequences can be found on pharmactuelle.fr, especially for pharmacies looking to quickly adjust their catalog.
Pharmacy remuneration reform: what the 2026-2027 negotiations are preparing
The other topic occupying discussions among colleagues is not technological: it is the overhaul of the pharmacy economic model. A ministerial meeting has relaunched work on remuneration, with a technical amendment expected to be finalized by September 2026.
A more ambitious structural amendment is in preparation, with a signature aimed for 2027. The stated goal is to shift towards a remuneration focused on clinical services and prevention rather than solely on the dispensing of medications. In practical terms, this would value pharmaceutical consultations, monitoring of chronic patients (diabetes, asthma, hypertension), and medication reviews.
For pharmacy owners, the practical question is straightforward: should they invest now in the setup of private consultation spaces and in training staff for new clinical missions, while financial modalities remain unclear? Opinions vary on this point, with some preferring to wait for the publication of amendments to calibrate their expenses.
Combating drug shortages: the stakes for pharmacies
Transparency requirements regarding stock and supply chain flows are gradually tightening for pharmaceutical establishments.
In pharmacies, this translates into concrete constraints:
- Obligation to report stock data more frequently for certain molecules identified as sensitive, which increases the daily administrative burden
- Strengthening the pharmacist’s role in proactive management of substitutions, with a heightened duty to inform patients when a usual treatment is unavailable
- Gradual implementation of digital tools for tracking shortages, connected to wholesalers and health agencies
For small pharmacies, the difficulty is not so much the rule itself but the adaptation of pharmacy management software (LGO). Publishers are rolling out updates, but integration takes time, and interfaces are not always intuitive.
AI and chatbots in pharmacies: between promise and ground reality
Artificial intelligence tools applied to pharmacy are multiplying. Health advice chatbots, drug interaction checkers, predictive stock management algorithms: the technological offering is expanding.
On the ground, adoption remains uneven. Chatbots integrated into pharmacy websites can filter simple requests (hours, product availability, prescription renewals) and free up time at the counter. Some AI solutions also help to automatically detect drug interactions during pharmaceutical validation, reducing the risk of error on complex prescriptions.
Predictive stock management represents another concrete use case. By analyzing sales history and seasonal data, these tools anticipate needs and limit overstocking. For a pharmacy managing several thousand references, the time savings are real.
However, the personalization of patient advice by AI remains in its infancy in community pharmacies. Health data is sensitive, regulatory frameworks are strict, and the pharmacist remains the final link in validation before any recommendation. AI assists; it does not replace clinical judgment.
Pharmacy and environment: pressure mounts on eco-responsibility
The environmental dimension is progressing in pharmacy practices, driven by both European regulation and patient demand. Reducing packaging, collecting unused medications, choosing eco-designed ranges: these topics are moving from marketing discourse to measurable actions.
Several levers are already activated in the most advanced pharmacies:
- Priority listing of natural health products with environmental certification
- Reduction of paper printing through the dematerialization of prescriptions and invoices
- Active participation in collection and recycling channels for single-use medical devices
The European pharmaceutical strategy pushes in this direction, with a framework that now integrates environmental impact into the life cycle assessment of medications. For pharmacies, eco-responsibility becomes a differentiation criterion among patients, not just a compliance constraint.
The coming months concentrate several simultaneous deadlines: publication of amendments on remuneration, adaptation to new rules on shortages, deployment of digital tools. Pharmacies that anticipate these changes by adjusting their organization, offering, and clinical skills now are better positioned than those that wait for the official publication of each text to react.